Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Jonathan A. Gutman, Amanda C. Winters, Andrew Kent, Maria L. Amaya, Christine M. McMahon, Clayton Smith, Craig T Jordan, Brett M. Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O'Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310117809